lifestyle.travelshq.com

Author: Silexion Therapeutics Corp

Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer

May 14, 2026
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

May 13, 2026
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer

April 28, 2026
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

March 24, 2026
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

March 24, 2026
Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 17, 2026
Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting

March 5, 2026
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

January 28, 2026